

FORM PTO-1390 (REV. 2-2005)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER 10589-013-999
<b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371</b>			
INTERNATIONAL APPLICATION NO. PCT/US2004/009572	INTERNATIONAL FILING DATE March 26, 2004	U.S. APPLICATION NO. (if known, see 37CFR 1.5) 60/458,079	
TITLE OF INVENTION <b>METHODS OF IDENTIFYING COMPOUNDS THAT TARGET tRNA SPLICING ENDONUCLEASE AND USES OF SAID COMPOUNDS AS ANTI-PROLIFERATIVE AGENTS</b>		PRIORITY DATE CLAIMED March 27, 2003	
APPLICANT(S) FOR DO/EO/US PTC Therapeutics, Inc.			
Applicant herewith submits to the United States Designated/ Elected Office (DO/EO/US) the following items and other information:			
<p>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</p> <p>4. <input checked="" type="checkbox"/> The U.S. has been elected (Article 31).</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)).</p> <p style="margin-left: 20px;">a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</p> <p style="margin-left: 20px;">b. <input checked="" type="checkbox"/> has been communicated by the International Bureau.</p> <p style="margin-left: 20px;">c. <input checked="" type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US)</p> <p>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).</p> <p style="margin-left: 20px;">a. <input type="checkbox"/> is attached hereto.</p> <p style="margin-left: 20px;">b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</p> <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))</p> <p style="margin-left: 20px;">a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</p> <p style="margin-left: 20px;">b. <input type="checkbox"/> have been communicated by the International Bureau.</p> <p style="margin-left: 20px;">c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p style="margin-left: 20px;">d. <input checked="" type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)) (unexecuted).</p> <p>10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p>			
<b>Items 11. to 20. below concern document(s) or information included:</b>			
<p>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input checked="" type="checkbox"/> A preliminary amendment.</p> <p>14. <input checked="" type="checkbox"/> An Application Data Sheet under 37 CFR 1.76.</p> <p>15. <input type="checkbox"/> A substitute specification.</p> <p>16. <input type="checkbox"/> A power of attorney and/or change of address letter.</p> <p>17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13<sup>ter</sup> 2 and 37 CFR 1.821- 1.825.</p> <p>18. <input type="checkbox"/> A second copy of the published International Application under 35 U.S.C. 154(d)(4).</p> <p>19. <input type="checkbox"/> A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4).</p> <p>20. <input checked="" type="checkbox"/> Other items or information: Copy of International Search Report, Copy of International Written Opinion and Transmittal Letter and Application Data Sheet Under 37 C.F.R. § 1.76.</p>			

US APPLICATION NO. (16 CFR 1.45) 60/458,079	10/551301	INTERNATIONAL APPLICATION NO. PCT/US2004/009572	ATTORNEY'S DOCKET NUMBER 10589-013-999
21. The following fees are submitted:			
<b>BASIC NATIONAL FEE:</b>			
<input checked="" type="checkbox"/> a) Basic national fee ..... <b>\$300.00</b> <input checked="" type="checkbox"/> b) Examination fee ..... Was the International Preliminary Examination Report prepared by the USPTO and do all filed claims in this U.S. application satisfy provisions of PCT Article 33(1)-(4) (i.e., novelty, inventive step and industrial capability)? ..... <input type="checkbox"/> i) Yes (\$100.00) ..... <input checked="" type="checkbox"/> ii) No (\$200.00) ..... <b>\$200.00</b> <input checked="" type="checkbox"/> c) Search fee ..... Was the USPTO the International Searching Authority? ..... <input checked="" type="checkbox"/> i) Yes (\$100.00) ..... ii) If no: <input type="checkbox"/> (a) An International Search Report will be provided to the USPTO on or before payment of the search fee. (\$400.00) ..... <input type="checkbox"/> (b) No International Search Report will be provided to the USPTO. (\$500.00) ..... <b>\$100.00</b>			
<b>TOTAL OF CALCULATIONS =</b> <b>\$ 600.00</b>			
<input checked="" type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing of computer programs listing filed in electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.			
Total Sheets 123 -100	Extra Sheets 23 /50	Number of each additional 50 or fraction thereof (round up to a whole number). 1	RATE x 250.00 <b>\$ 250.00</b>
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).			
CLAIMS Total Claims	NUMBER FILED 93 - 20	NUMBER EXTRA 73	RATE X x \$50.00 <b>\$ 3,650.00</b>
Independent Claims	7 - 3	4	x \$200.00 = <b>\$ 800.00</b>
<input checked="" type="checkbox"/> MULTIPLE DEPENDENT CLAIM(S) (if applicable) <b>+ 360.00</b>			
<b>TOTAL OF ABOVE CALCULATIONS=</b> <b>\$ 5,790.00</b>			
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 50%			
<b>SUBTOTAL =</b> <b>\$ 2,895.00</b>			
Surcharge of \$130.00 for furnishing the English Translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).			
<b>TOTAL NATIONAL FEE</b> <b>= \$ 3,025.00</b>			
Fee for recording the enclosed assignment (37 CFR 1.21 (h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). 0 x \$40.00 per property			
<b>TOTAL FEES ENCLOSED</b> <b>= \$ 3,025.00</b>			
<b>Amount to be refunded:</b>			
<b>charged:</b> <b>\$ 3,025.00</b>			
a. <input type="checkbox"/> A check in the amount of \$ to cover the above fees is enclosed. b. <input checked="" type="checkbox"/> This is an estimate of the fees due. Please charge Deposit Account No. 50-3013 to cover the required fees. A copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-3013. A copy of this sheet is enclosed.			
Note: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the International Application to pending status.			
22. <input type="checkbox"/> Other instructions			
23. <input checked="" type="checkbox"/> All correspondence for this application should be mailed to JONES DAY customer no. 20583			
24. <input type="checkbox"/> All telephone inquiries should be made to			
Laura A. Coruzzi NAME	SIGNATURE <i>Laura A. Coruzzi</i>	30,742 REG. NO.	September 27, 2005 DATE

Express Mail No.: EV 531 712 849 US

PATENT IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Christopher Trotta

Confirmation No.: To be assigned

Application No.: To be assigned; National Stage  
Application of International  
Application PCT/US2004/009572

Art Unit: To be assigned

Int'l Filing Date: March 26, 2004

Examiner: To be assigned

For: METHODS FOR IDENTIFYING COMPOUNDS  
THAT TARGET tRNA SPLICING  
ENDONUCLEASE AND USES OF SAID  
COMPOUNDS AS ANTI-PROLIFERATIVE  
AGENTS

Attorney Docket No.: 10589-013-999

TRANSMITTAL

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

In connection with the filing of the above-identified application, transmitted herewith are the following documents:

1. Transmittal Letter to the United States Designated/Elected Office (in duplicate);
2. Copy of the International Application as filed;
3. Copy of International Publication No. WO 2004/087069 A2;
4. Copy of International Search Report;
5. Copy of International Written Opinion;
6. Preliminary Amendment Under 37 C.F.R. § 1.115;
7. Application Data Sheet Under 37 C.F.R. § 1.76; and
8. Unexecuted Declaration of the inventor.

Entry of the documents transmitted herewith is respectfully requested.

This application is a National Stage Application of International Application No. PCT/US2004/009572 filed March 26, 2004, which claims benefit of U.S. Provisional Application No. 60/458,079 filed March 27, 2003.

Respectfully submitted,

Date: September 27, 2005



Laura A. Coruzzi  
Jones Day  
222 East 41<sup>st</sup> Street  
New York, NY 10017  
Attorneys for Applicant

30,742  
Reg. No.

Enclosures